Lp(a): A Rapidly Evolving Therapeutic Landscape.

Autor: Anchouche K; McGill University Health Centre and Research Institute, Montréal, Québec, Canada.; McGill University, Montréal, Québec, Canada., Thanassoulis G; McGill University Health Centre and Research Institute, Montréal, Québec, Canada. george.thanassoulis@mcgill.ca.; McGill University, Montréal, Québec, Canada. george.thanassoulis@mcgill.ca.
Jazyk: angličtina
Zdroj: Current atherosclerosis reports [Curr Atheroscler Rep] 2024 Nov 22; Vol. 27 (1), pp. 7. Date of Electronic Publication: 2024 Nov 22.
DOI: 10.1007/s11883-024-01252-0
Abstrakt: Purpose of Review: Elevated lipoprotein(a) (Lp[a]) is a genetically determined cardiovascular risk factor, causally linked to both atherosclerotic coronary artery disease and aortic stenosis. Elevated Lp(a) is widely prevalent, and several cardiovascular societies now recommend performing Lp(a) screening at least once in all adults. However, there are currently no approved drugs aimed specifically at lowering Lp(a). In this review, we describe several promising Lp(a)-lowering therapies in the drug development pipeline and outline what role these may have in future clinical practice.
Recent Findings: Pelacarsen and olpasiran are two novel RNA-based injectable therapies which are being studied in ongoing phase 3 clinical trials, with the earliest of these to be concluded in 2025. These drugs act by degrading transcribed LPA mRNA, which would normally yield the apolipoprotein(a) constituent of Lp(a). Other candidate drugs, such as Lepodisiran, Zerlasiran, and Muvalaplin, are also in early-stage development. While there are presently no Lp(a)-lowering drugs available for routine clinical use, several promising candidates are currently under investigation. If these prove to be effective in randomized clinical trials, they will expand the cardiovascular care armamentarium and will allow clinicians to treat a presently unmitigated cardiovascular risk factor.
Competing Interests: Declarations. Human and Animal Rights and Informed Consent: No animal or human subjects were used by the authors in this study. Competing Interests: Dr. Thanassoulis has received consulting fees from Ionis Pharmaceuticals; and has participated in advisory boards for Amgen, Sanofi, Novartis, HLS Therapeutics, New Amsterdam, Novo Nordisk and Silence. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: